Nitric oxide plasma concentration associated with cognitive impairment in patients with recurrent depressive disorder

Neuroscience Letters

Volumn 510, Issue 2, 2012, Pages 127-131

  Talarowska, Monika ^a   Gałecki, Piotr ^a   Maes, Michael ^b   Orzechowska, Agata ^a   Chamielec, Marcelina ^a   Bartosz, Grzegorz ^a,c   Kowalczyk, Edward ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b Piyavate Hospital   (Thailand)

^c UNIVERSITY OF RZESZÓW   (Poland)

Author keywords

Cognitive impairment; Depression; Nitric oxide

Indexed keywords

NITRIC OXIDE;

ADULT; ARTICLE; AUDITORY MEMORY; AUDITORY VERBAL LEARNING TEST; CLINICAL ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HAMILTON SCALE; HUMAN; MALE; MENTAL FUNCTION; MENTAL PERFORMANCE; PRIORITY JOURNAL; PSYCHOLOGIC TEST; RECURRENT DISEASE; STROOP TEST; VERBAL FLUENCY TEST; VISUAL MEMORY; WORKING MEMORY;

ADULT; COGNITION DISORDERS; DEPRESSIVE DISORDER; FEMALE; HUMANS; MALE; MEMORY; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; NITRIC OXIDE; RECURRENCE; YOUNG ADULT;

EID: 84856772767     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2012.01.018     Document Type: Article

References (47)

1. Aktan F. iNOS-mediated nitric oxide production and its regulation. Life Sci. 2004, 75(6):639-653.
2. 99Tc‴-ECD brain SPECT. Nucl. Med. Commun. 2001, 22:135-143.
3. Austin S.A., Santhanam A.V., Katusic Z.S. Endothelial nitric oxide modulates expression and processing of amyloid precursor protein. Circ. Res. 2010, 107(12):1498-1502.
4. Ballantyne C.M., Nambi V. Markers of inflammation and their clinical significance. Atheroscler. Suppl. 2005, 6(2):21-29.
5. Bell I.R., Edman J.S., Selhub J., Morrow F.D., Marby D.W., Kayne H.L., Cole J.O. Plasma homocysteine in vascular disease and in nonvascular dementia of depressed elderly people. Acta Psychiatr. Scand. 1992, 86(5):386-390.
6. Cai Z.Y., Yan Y., Sun S.Q., Zhang J., Huang L.G., Yan N., Wu F., Li J.Y. Minocycline attenuates cognitive impairment and restrains oxidative stress in the hippocampus of rats with chronic cerebral hypoperfusion. Neurosci. Bull. 2008, 24(5):305-313.
7. Chrapko W., Jurasz P., Radomski M.W., Archer S.L., Newman S.C., Baker G., Lara N., Le Mellédo J.M. Alteration of decreased plasma NO metabolites and platelet NO synthase activity by paroxetine in depressed patients. Neuropsychopharmacology 2006, 31(6):1286-1293.
8. de la Torre J.C., Aliev G. Inhibition of vascular nitric oxide after rat chronic brain hypoperfusion: spatial memory and immunocytochemical changes. J. Cereb. Blood Flow Metab. 2005, 25(6):663-672.
9. Demyttenaere K., De Fruyt J. Getting what you ask for: on the selectivity of depression rating scales. Psychother. Psychosom. 2003, 72:61-70.
10. Durán W.N., Breslin J.W., Sánchez F.A. The NO cascade, eNOS location, and microvascular permeability. Cardiovasc. Res. 2010, 87(2):254-261.
11. El Kossi M.M., Zakhary M.M. Oxidative stress in the context of acute cerebrovascular stroke. Stroke 2000, 31(8):1889-1892.
12. Faraci F.M. Protecting against vascular disease in brain. Am. J. Physiol. Heart Circ. Physiol. 2011, 300(5):1566-1582.
13. Gkaliagkousi E., Ferro A. Nitric oxide signalling in the regulation of cardiovascular and platelet function. Front. Biosci. 2011, 16:1873-1897.
14. Gualtieri C.T., Johnson L.G. Age-related cognitive decline in patients with mood disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32(4). 962-927.
15. Haensel A., Bardwell W.A., Mills P.J., Loredo J.S., Ancoli-Israel S., Morgan E.E., Heaton R.K., Dimsdale J.E. Relationship between inflammation and cognitive function in obstructive sleep apnea. Sleep Breath. 2009, 13(1):35-41.
16. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 1960, 23:56-62.
17. Hayashi T., Nomura H., Osawa M., Funami J., Miyazaki A., Iguchi A. Nitric oxide metabolites are associated with survival in older patients. J. Am. Geriatr. Soc. 2007, 55(9):1398-13403.
18. Herken H., Gurel A., Selek S., Armutcu F., Ozen M.E., Bulut M., Kap O., Yumru M., Savas H.A., Akyol O. Adenosine deaminase, nitric oxide, superoxide dismutase, and xanthine oxidase in patients with major depression: impact of antidepressant treatment. Arch. Med. Res. 2007, 38(2):247-252.
19. Hritcu L., Ciobica A., Stefan M., Mihasan M., Palamiuc L., Nabeshima T. Spatial memory deficits and oxidative stress damage following exposure to lipopolysaccharide in a rodent model of Parkinson's disease. Neurosci. Res. 2011, 71(1):35-43.
20. ICD-10 Classification of Mental & Behavioural Disorders 1993, World Health Organization.
21. Kim Y.K., Paik J.W., Lee S.W., Yoon D., Han C., Lee B.H. Increased plasma nitric oxide level associated with suicide attempt in depressive patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006, 30(6):1091-1096.
22. Kleinert H., Pautz A., Linker K., Schwarz P.M. Regulation of the expression of inducible nitric oxide synthase. Eur. J. Pharmacol. 2004, 500(1-3):255-266.
23. Küçükatay V., Hacioĝlu G., Ozkaya G., Aĝar A., Yargiçoĝlu P. The effect of diabetes mellitus on active avoidance learning in rats: the role of nitric oxide. Med. Sci. Monit. 2009, 15(3):88-93.
24. Lehmann M., Gottfries C.G., Regland B. Identification of cognitive impairment in the elderly: homocysteine is an early marker. Dement. Geriatr. Cogn. Disord. 1999, 10(1):12-20.
25. Li G., Wang L.Y., Shofer J.B., Thompson M.L., Peskind E.R., McCormick W., Bowen J.D., Crane P.K., Larson E.B. Temporal relationship between depression and dementia: findings from a large community-based 15-year follow-up study. Arch. Gen. Psychiatry 2011, 68(9):970-977.
26. Łuria A. Neuropsychology 1976, PZWL, Warsaw.
27. Maes M., Yirmyia R., Noraberg J., Brene S., Hibbeln J., Perini G., Kubera M., Bob P., Lerer B., Maj M. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab. Brain Dis. 2009, 24(1):27-53.
28. Mangiafico R.A., Sarnataro F., Mangiafico M., Fiore C.E. Impaired cognitive performance in asymptomatic peripheral arterial disease: relation to C-reactive protein and D-dimer levels. Age Ageing 2006, 35(1):60-65.
29. Manukhina E.B., Pshennikova M.G., Goryacheva A.V., Khomenko I.P., Mashina S.Y., Pokidyshev D.A., Malyshev I.Y. Role of nitric oxide in prevention of cognitive disorders in neurodegenerative brain injuries in rats. Bull. Exp. Biol. Med. 2008, 146(4):391-395.
30. Marazziti D., Consoli G., Picchetti M., Carlini M., Faravelli L. Cognitive impairment in major depression. Eur. J. Pharmacol. 2010, 626(1):83-86.
31. McDowd J., Hoffman L., Rozek E., Lyons K.E., Pahwa R., Burns J., Kemper S. Understanding verbal fluency in healthy aging, Alzheimer's disease, and Parkinson's disease. Neuropsychology 2011, 25(2):210-225.
32. Moonseong H., Murphy C.F., Meyers B.S. Relationship between the Hamilton Depression Rating Scale and the Montgomery-åsberg Depression Rating Scale in depressed elderly. Am. J. Geriatr. Psychiatry 2007, 15:899-905.
33. Nanetti L., Raffaelli F., Vignini A., Perozzi C., Silvestrini M., Bartolini M., Provinciali L., Mazzanti L. Oxidative stress in ischaemic stroke. Eur. J. Clin. Invest. 2011, 10.1111/j. 1365-2362.2011.02546.x.
34. Patten S. Performance of the composite international diagnostic interview short form for major depression in community and clinical samples. Chron. Dis. Can. 1997, 3:18-24.
35. Reitan R.M. The relation of the trail making test to organic brain damage. J. Cons. Psychol. 1958, 19:393-394.
36. Rojas-Fernandez C.H., Moorhouse P. Current concepts in vascular cognitive impairment and pharmacotherapeutic implications. Ann. Pharmacother. 2009, 43(7):1310-1323.
37. Sánchez-Cubillo I., Periáñez J., Adrover-Roig D., Rodríguez-Sánchez J., Ríos-Lago M., Tirapu J. Construct validity of the Trail Making Test: role of task-switching, working memory, inhibition/interference control, and visuomotor abilities. JINS 2009, 15:438-451.
38. Selley M.L. Increased concentrations of homocysteine and asymmetric dimethylarginine and decreased concentrations of nitric oxide in the plasma of patients with Alzheimer's disease. Neurobiol. Aging 2003, 24(7):903-907.
39. Solfrizzi V., D'Introno A., Colacicco A.M., Capurso C., Todarello O., Pellicani V., Capurso S.A., Pietrarossa G., Santamato V., Capurso A., Panza F. Circulating biomarkers of cognitive decline and dementia. Clin. Chim. Acta 2006, 364(1-2):91-112.
40. Stroop J.R. Studies of interference in serial verbal reactions. J. Exp. Psychol. 1935, 18:643-662.
41. Suzuki E., Yagi G., Nakaki T., Kanba S., Asai M. Elevated plasma nitrate levels in depressive states. J. Affect. Disord. 2001, 63(1-3):221-224.
42. Talarowska M., Florkowski A., Zboralski K., Berent D., Wierzbiński P., Gałecki P. Auditory-verbal declarative and operating memory among patients suffering from depressive disorders - preliminary study. Adv. Med. Sci. 2010, 55(2):317-327.
43. Tseng I.J., Liu H.C., Yuan R.Y., Sheu J.J., Yu J.M., Hu C.J. Expression of inducible nitric oxide synthase (iNOS) and period 1 (PER1) clock gene products in different sleep stages of patients with cognitive impairment. J. Clin. Neurosci. 2010, 17(9):1140-1143.
44. Umur E.E., Oktenli C., Celik S., Tangi F., Sayan O., Sanisoglu Y.S., Ipcioglu O., Terekeci H.M., Top C., Nalbant S., Kucukardali Y. Increased iron and oxidative stress are separately related to cognitive decline in elderly. Geriatr. Gerontol. Int. 2011, 11(4):504-509.
45. Vignini A., Nanetti L., Moroni C., Tanase L., Bartolini M., Luzzi S., Provinciali L., Mazzanti L. Modifications of platelet from Alzheimer disease patients: a possible relation between membrane properties and NO metabolites. Neurobiol. Aging 2007, 28(7):987-994.
46. Vinkers D.J., van der Mast R.C. Temporal course of depressive symptoms during the development of Alzheimer disease: blowing hot and cold over depression and cognitive impairment. Neurology 2011, 76(17):1531.
47. Wolfram H., Neumann J., Wieczorek V. Psychologische leistungstests in der neurologie und psychiatrie 1986, VEB Georg Thieme, Leipzig.